There is no doubt that Zoetis Inc (ZTS) ticks all the boxes.

With 1.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.82 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $197.00 whereas the lowest price it dropped to was $195.00. The 52-week range on ZTS shows that it touched its highest point at $201.92 and its lowest point at $151.03 during that stretch. It currently has a 1-year price target of $226.38. With its current market cap of 89.87 billion, ZTS has annualized dividend of $1.48 while the current yield stands at 0.76%. Beta for the stock currently stands at 0.87.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZTS was up-trending over the past week, with a rise of 3.49%, but this was down by -0.10% over a month. Three-month performance surged to 17.10% while six-month performance rose 3.38%. The stock gained 18.23% in the past year, while it has lost -0.82% so far this year. A look at the trailing 12-month EPS for ZTS yields 4.92 with Next year EPS estimates of 5.96. For the next quarter, that number is 1.32. This implies an EPS growth rate of 10.88% for this year and 10.20% for next year. EPS is expected to grow by 10.45% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 20.76%.

Float and Shares Shorts:

At present, 501.89 million ZTS shares are outstanding with a float of 458.49 million shares on hand for trading. On Jan 11, 2024, short shares totaled 2.75 million, which was 0.60% higher than short shares on Dec 14, 2023. In addition to Ms. Kristin C. Peck as the firm’s CEO & Director, Mr. Wetteny N. Joseph serves as its Executive VP & CFO.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZTS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZTS analysts setting a high price target of $255.00 and a low target of $203.00, the average target price over the next 12 months is $226.38. Based on these targets, ZTS could surge 30.27% to reach the target high and rise by 3.7% to reach the target low. Reaching the average price target will result in a growth of 15.65% from current levels.

Summary of Insider Activity:

Insiders traded ZTS stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 923 shares were sold. The number of buy transactions has increased to 30 while that of sell transactions has risen to 36 over the past year. The total number of shares bought during that period was 101,868 while 89,785 shares were sold.